Relevant bibliographies by topics / Acute Leukaemia - Treatment / Books
To see the other types of publications on this topic, follow the link: Acute Leukaemia - Treatment.

Books on the topic 'Acute Leukaemia - Treatment'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 15 books for your research on the topic 'Acute Leukaemia - Treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. London: National Institute for Clinical Excellence, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. London: National Institute for Clinical Excellence, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rooney, Maria Anne. An evaluation of the immune competence of children with common Acute Lymphoblastic Leukaemia, both during and post-treatment, by an investigation of the Lymphocyte sub-populations using monoclonal antibodies and the Alkaline Phosphatase Anti-Alkaline Phosphatase technique. [s.1: The Author], 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mendez, Irvin. Acute Myeloid Leukaemia: Symptoms, Diagnosis and Treatment. Nova Science Publishers, Incorporated, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

M, Carella Angelo, ed. Chronic myeloid leukaemia: Biology and treatment. London: Martin Dunitz, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Goldman, John M., Angelo M. Carella, George Q. Daley, Connie J. Eaves, and Hehlmann Rudiger. Chronic Myeloid Leukaemia: Biology and Treatment. Taylor & Francis Group, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

McCann, Shaun R. Leukaemia. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198717607.003.0007.

Full text
Abstract:
The word leukaemia still is associated with foreboding and a fear of premature death. Steady advances have been made in the treatment of childhood leukaemia but, with notable exceptions, the same is not true in adults. The so-called genetic/molecular revolution has extended the understanding of the pathogenesis of many forms of leukaemia but, as yet, has rarely facilitated cure. With the introduction of tyrosine kinase inhibitor therapy, chronic myeloid leukaemia is the obvious exception but it still needs to be seen as to whether the cytogenetic/molecular revolution can provide cures for many elderly patients with leukaemia, as such patients respond poorly to chemotherapy. Haematopoietic stem cell transplantation, although toxic, expensive, and difficult, still provides a cure for many patients. In spite of all these advances, however, most adults with acute leukaemia or myelodysplastic syndrome are destined to die from their disease, and the causes of these fatal illnesses continue to elude researchers.
APA, Harvard, Vancouver, ISO, and other styles
8

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Bone and soft tissue malignancies. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689842.003.0025.

Full text
Abstract:
Haematological malignancies examines the epidemiology, genetics, clinical presentation and classification of these diseases, and presents current treatment approaches for each. First are the acute leukaemias, and the management of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Chronic myeloid leukaemia, its genetics and sensitivity to tyrosine kinase inhibitors, is described. Myelodysplastic syndromes and their management, are followed by chronic lymphoid leukaemias, a large heterogeneous group of diseases, and their treatment. Hodgkin lymphoma, its pathology and presentation, staging and role of PET scanning, is described along with current treatment with chemotherapy and limited radiotherapy. Non-Hodgkin lymphoma is another heterogeneous group of diseases, divided into low-grade and high-grade pathology, and varying in their genetics, presentation, and management. Rituximab is a key component of chemotherapy regimens against B-cell lymphoma. Myeloma and other plasma cell dyscrasias are described, and treatment options reviewed. Myeloma remains incurable, but with appropriate management consistent with prolonged good quality life. Treatment includes chemotherapy, bisphosphonate therapy, analgesics and radiotherapy, Throughout this chapter is emphasised the importance of clinical trials in driving the rapid improvements in treatment of these diseases.
APA, Harvard, Vancouver, ISO, and other styles
9

Cutter, David, and Martin Scott-Brown. Treatment of cancer. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0325.

Full text
Abstract:
The variety of conditions that are considered to be ‘cancer’ is extremely wide, with marked variation in the management approach from disease to disease. A common feature in the management of malignant conditions, however, is the involvement of a wide range of medical professionals at different stages of the patient pathway. This commonly includes physicians, surgeons, radiologists, pathologists, medical oncologists, radiation oncologists, and specialist nurses, as well as a plethora of other allied disciplines. As such, a practice that has been widely adopted is to work as a multidisciplinary team (MDT), with regular meetings to decide the appropriate treatment for each patient with a cancer diagnosis, on an individual and case-by-case basis. The main treatment modalities for the treatment of cancer are surgery, radiotherapy, and chemotherapy. While these are often combined to form a multimodality therapy, they are all, in isolation, potentially radical (curative) therapies for certain conditions. For example, surgery (in the case of a Stage I colon adenocarcinoma), radiotherapy (in the case of early laryngeal squamous cell carcinoma), and chemotherapy (in the case of acute lymphoblastic leukaemia) are all curative as single-modality treatments. It is commonly the case, however, for a patient to require more than one mode of therapy to achieve the best outcome, for example a combination of surgery, chemotherapy, and radiotherapy for early breast cancer. It can also be the case that two or more different management strategies are thought to give equivalent oncological results, for example surgery or radiotherapy for early prostate cancer. In this situation, the MDT and the patient need to decide on the ‘best’ management plan for the individual, based on their personal and professional opinions and on the differing toxicity profiles of the alternate treatments.
APA, Harvard, Vancouver, ISO, and other styles
10

McCann, Shaun R. Molecules, genes, and gene therapy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198717607.003.0009.

Full text
Abstract:
The twenty-first century has brought many innovations in haematology, with improved diagnostic technology, which may inform treatment choices for malignant diseases, and a better understanding of the genetics and/or epigenetics underlying many diseases. Unfortunately, the aetiology of most of these diseases still eludes us, and some common diseases such as sickle cell disease await simple, inexpensive, and widely available curative treatment. For reasons that are often obscure, some diseases have become fashionable and attract large research financial backing, whereas some do not. With the advent of advanced technology and an improved understanding of disease mechanisms, most haematological malignancies should enjoy the same success as the treatment of childhood acute lymphoblastic leukaemia and chronic myeloid leukaemia.
APA, Harvard, Vancouver, ISO, and other styles
11

Acute Leukaemias (Haematology & Blood Transfusion). Springer-Verlag Berlin and Heidelberg GmbH & Co. K, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

(Editor), Gunther Schellong, Wolfgang Hiddemann (Editor), and Jorg Ritter (Editor), eds. Acute Leukaemias (Haematology and blood transfusion). Springer-Verlag Berlin and Heidelberg GmbH & Co. K, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

McCann, Shaun R. Combination chemotherapy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198717607.003.0012.

Full text
Abstract:
One of the major advances in haematology during the past six decades has been the development of combination chemotherapy. However, some would dispute the claim that combination chemotherapy has been a major therapeutic advance, arguing that survival for most common cancers has not improved since the advent of chemotherapy. It is certainly true that the survival of children with acute lymphoblastic leukaemia has improved and that the drug imatinib mesylate and its derivatives have changed the outcome for most patients with chronic myeloid leukaemia. Likewise, combination chemotherapy has greatly modified the prognosis for patients with Hodgkin lymphoma and some types of non-Hodgkin lymphoma. However, it must be said that the application of combination chemotherapy to common non-haematological cancers has not met with similar success. In this chapter, the practicalities of the treatment of blood disorders are discussed, with specific reference to the use of this therapy by the medical profession.
APA, Harvard, Vancouver, ISO, and other styles
14

Provan, Drew, Trevor Baglin, Inderjeet Dokal, and Johannes de Vos. Protocols and procedures. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199683307.003.0015.

Full text
Abstract:
Acute leukaemia: investigations - Platelet reactions and refractoriness - Prophylactic regimen for neutropenic patients - Guidelines for use of IV antibiotics in neutropenic patients - Treatment of neutropenic sepsis: source unknown - Treatment of neutropenic sepsis: source known/suspected - Prophylaxis for patients treated with purine analogues - Tumour lysis syndrome - Administration of chemotherapy - Antiemetics for chemotherapy - Intrathecal chemotherapy - Management of extravasation - Specific procedures after extravasation of cytotoxics commonly used in haematology - Anticoagulation therapy: heparin - Oral anticoagulation with VKA - Oral anticoagulation with NOAC - Management of needlestick injuries - Chemotherapy protocols - ABVD - BEACOPP/escalated BEACOPP - BEAM/LEAM - Bortezomib/dexamethasone - CHOP 21 and CHOP 14 - ChlVPP - CODOX-M/IVAC ± R - CTD and CTDa - DHAP ± R - ESHAP ± R - FC ± R - ICE ± R - Lenalidomide/dexamethasone - MPT - Mini-BEAM ± R - Nordic schedule (R-maxi-CHOP and R-high-dose cytarabine for MCL) - PMitCEBO - R-Bendamustine - R-CHOP - R-CVP and CVP - Rituximab: monotherapy and maintenance therapy - Stanford V
APA, Harvard, Vancouver, ISO, and other styles
15

Provan, Drew, Trevor Baglin, Inderjeet Dokal, Johannes de Vos, and Mammit Kaur. Protocols and procedures. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199683307.003.0015_update_001.

Full text
Abstract:
Acute leukaemia: investigations - Platelet reactions and refractoriness - Prophylactic regimen for neutropenic patients - Guidelines for use of IV antibiotics in neutropenic patients - Treatment of neutropenic sepsis: source unknown - Treatment of neutropenic sepsis: source known/suspected - Prophylaxis for patients treated with purine analogues - Tumour lysis syndrome - Administration of chemotherapy - Antiemetics for chemotherapy - Intrathecal chemotherapy - Management of extravasation - Specific procedures after extravasation of cytotoxics commonly used in haematology - Anticoagulation therapy: heparin - Oral anticoagulation with VKA - Oral anticoagulation with NOAC - Management of needlestick injuries - Chemotherapy protocols - ABVD - BEACOPP/escalated BEACOPP - BEAM/LEAM - Bortezomib/dexamethasone - CHOP 21 and CHOP 14 - ChlVPP - CODOX-M/IVAC ± R - CTD and CTDa - DHAP ± R - ESHAP ± R - FC ± R - ICE ± R - Lenalidomide/dexamethasone - MPT - Mini-BEAM ± R - Nordic schedule (R-maxi-CHOP and R-high-dose cytarabine for MCL) - PMitCEBO - R-Bendamustine - R-CHOP - R-CVP and CVP - Rituximab: monotherapy and maintenance therapy - Stanford V
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Acute Leukaemia - Treatment' for other source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography